Immunotherapy provides long-term survival benefit: Further evidence in lung cancer

Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.Researchers presented the three-year survival results of the randomised phase 2 POPLAR trial in second line, which is the longest follow-up reported to date with anti-programmed death ligand 1 (PD-L1) immunotherapy in patients with previously treated, advanced non-small-cell lung cancer (NSCLC).

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

ELCC 2018 [+]    European Lung Cancer Congress [+]    Geneva [+]    Switzerland [+]    Researchers [+]    POPLAR [+]    NSCLC [+]   

More #news: